(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote In favor of Your Favored Web-based Book Retailor - 2Why the UAE has incurred the wrath of Somalia
- 3Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- 4The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- 57 Logically Demonstrated Techniques for Better Rest
- Figure out how to Guarantee Your Dental Embeds Endure forever
- Asia's Noteworthy Destinations: A Voyager's Aide
- The Job of a Migration Legal advisor: How They Can Help You
- Vote in favor of your Number one Kind of Shades
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Figure out How to Adjust Work, Life, and an Internet based Degree
